English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/3392
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Citado 42 veces en Web of Knowledge®  |  Pub MebCentral Ver citas en PubMed Central  |  Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar otros formatos: Exportar EndNote (RIS)Exportar EndNote (RIS)Exportar EndNote (RIS)
Título : Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau
Autor : Santa María, Ismael ; Hernández Pérez, Félix; Río, Joaquín del; Moreno Muñoz, Francisco José; Ávila, Jesús
Fecha de publicación : 6-sep-2007
Editor: BioMed Central
Citación : Mol Neurodegener. 2007; 2: 17
Resumen: Alzheimer's disease (AD) is characterized by the presence of two histopathological hallmarks; the senile plaques, or extracellular deposits mainly composed of amyloid-β peptide (Aβ), and the neurofibrillary tangles, or intraneuronal inclusions composed of hyperphosphorylated tau protein. Since Aβ aggregates are found in the pathological cases, several strategies are under way to develop drugs that interact with Aβ to reduce its assembly. One of them is 3-amino-1-propane sulfonic acid (Tramiprosate, 3-APS, Alzhemed™), that was developed as a sulfated glycosaminoglycan mimetic, that could interact with Aβ peptide, preventing its aggregation. However, little is known about the action of 3-APS on tau protein aggregation. In this work, we have tested the action of 3-APS on cell viability, microtubule network, actin organization and tau aggregation. Our results indicate that 3-APS favours tau aggregation, in tau transfected non-neuronal cells, and in neuronal cells. We also found that 3-APS does not affect the binding of tau to microtubules but may prevent the formation of tau-actin aggregates. We like to emphasize the importance of testing on both types of pathology (amyloid and tau) the potential drugs to be used for AD treatment.
Descripción : This article is available from: http://www.molecularneurodegeneration.com/content/2/1/17
URI : http://hdl.handle.net/10261/3392
DOI: 10.1186/1750-1326-2-17
ISSN: 1750-1326
Aparece en las colecciones: (CBM) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
picrender.pdfPrincipal684,34 kBAdobe PDFVista previa
Visualizar/Abrir
1750-1326-2-17-S1.pdfArchivo adicional 1415,12 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 



NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.